Form D · Biotechnology
Aperiam Bio, Inc.
Austin, TX · CIK 0001911739
Offering snapshot reported Sep 27, 2023 · SEC filing
- Reported sold
- $4M Indefinite offering
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Sep 18, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 27, 2023 | Initial | $3,999,996 | No comparison | 2 | SEC filing |
| Mar 7, 2022 | Initial | $3,660,002 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-493177
Source: Form D, filed Sep 27, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Austin Cole | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2205 North Lamar Blvd. Unit 511
Austin, TX, 78705
Austin, TX, 78705